### Receive the CCTS Newsletter: go.uab.edu/JoinTheCCTS

Follow us on Twitter: @cctsnetwork

Check out upcoming events: go.uab.edu/cctsevents

Catch past events anytime: go.uab.edu/cctsvideochannel








### **Zoom Etiquette**

- Everyone will be muted.
- To ask a question, please use the Zoom chat box.
- Questions will be answered **after** the last speaker as time permits.
- In chat box, please include question, your name and email address.
- If your question is not answered, you will be emailed an answer by one of our speakers after the workshop.
- We appreciate your patience and cooperation.
- Slides, resources, and recording of session will be placed on the CCTS Clinical Trials Kiosk under the Budget Tools.



# https://www.uab.edu/ccts/clinical-research/clinical-trials-kiosk







CCTS Forms CCTS Quicklinks CCTS Video Channel UAB Quicklinks

Partner Network Research Commons Training Academy Clinical Research Engagement of Communities Special Modules News & Events About

Getting Started in Clinical Research

Clinical Trials Kiosk

Clinical Services

Telehealth Resources for Clinical Researchers

Trainings

**OnCore** 

Team

Resources

Clinical Trials Lifecycle

CITP on the Go Podcast

#### Contact

Meredith Fitz-Gerald, MSN,

RN

Director, Clinical Research

Support Program

### **WELCOME TO THE CLINICAL TRIALS KIOSK:**

EVERYTHING YOU NEED FOR CLINICAL TRIALS RESEARCH



**UAB Research Administration Offices** 

COVID-19 Support Documents & Resources

Resources for Conducting Clinical Research

Source Documents, Tools & Templates

Investigator Toolkit

Recruitment & Retention

Study Coordinator Tr Starter Kit

**Budget Toolkit** 

Corrective Action and Preventative Plan (CAPA)





### Clinical Research Budget Workshop

**Session One**: Feasibility, Recruitment and Retention- A Team Approach

Meredith B. Fitz-Gerald, RN, MSN
Certificate in Clinical Research Management
Director of the CCTS Clinical Research Support Program (CRSP)
The University of Alabama at Birmingham (UAB)

Dana Rizk, MD
Professor of Medicine, Nephrology Division
Director of Clinical Trials Research
Medical Director of Clinical Trials Administrative Office The University of Alabama at Birmingham (UAB)

ACCELERATE. INNOVATE. DISSEMINATE. WITH YOUR CCTS.

### **Objectives:**

- Demonstrate use of Feasibility Worksheet and importance of assessment
- Enhance knowledge of team approach Promote collaboration of entire Research team- PI, Coordinators, Regulatory, Finance, Data Management
- Promote use and stress importance of having a Recruitment and Retention plan.





# Feasibility Analysis or Assessment (FA)

### What is a FA?

Process of evaluating the possibility of conducting a clinical study.

### Why is a FA important?

- Investment of time, ensures you are choosing the right fit for your program.
- Identifies potential challenges.

Overall objective = optimal project completion





# Feasibility Checklist / Analysis Tool

 It is completed by study team and PI after review of protocol, consent form, draft budget and other related study materials.

- It is your best estimate of resources.
- It documents your desire and capability to participate in compliance with protocol requirements.


https://www.uab.edu/ccts/images/UAB Protocol Feasibility Form 2021.pdf







### https://www.uab.edu/ccts/clinical-research/clinical-trial-kiosk





#### Center for Clinical and Translational Science

Search

CCTS Forms CCTS Quicklinks CCTS Video Channel UAB Quicklinks

Partner Network Research Commons Training Academy Clinical Research Engagement of Communities Special Modules News & Events About

#### **Current Covid Health and Safety Guidelines**

Getting Started in Clinical Research

Clinical Trials Kiosk

Clinical Services

Telehealth Resources for Clinical Researchers

Trainings

OnCore

Team

Resources

Clinical Trials Lifecycle

CITP on the Go Podcast

#### Contact

Meredith Fitz-Gerald, MSN, RN

Director, Clinical Research Support Program

mfitzgerald@uabmc.edu

205 975 2759

#### **WELCOME TO THE CLINICAL TRIALS KIOSK:**

**EVERYTHING YOU NEED FOR CLINICAL TRIALS RESEARCH** 



**UAB Research Administration Offices** 

COVID-19 Support Documents & Resources

Resources for Conducting Clinical Research

Source Documents, Tools & Templates

Investigator Toolkit

Recruitment & Retention

Study Coordinator Trial Starter Kit

**Budget Toolkit** 

Corrective Action and Preventative Plan (CAPA)

Standard Operating Procedures (SOPs) Templates





### Sample Feasibility Assessment Tool Key Sections

uab A  col #: ple Investigator: or/CRO: Phase: Administration: critical descriptor lation at is the population age: at is the subject health s at type of treatment pop equired? at is the number of patie ected to enroll? en number of paties colled at this site realistic	Phase I PO		□ Pha	
ple Investigator: or/CRO: Phase: Article: Administration: critical descriptor lation at is the population age: at is the subject health s at type of treatment pop equired? at is the number of patie ected to enroll? en unmber of patients to	PO tatus?	sq		Comments
ple Investigator: or/CRO: Phase: Article: Administration: critical descriptor lation at is the population age: at is the subject health s at type of treatment pop equired? at is the number of patie ected to enroll? en unmber of patients to	PO tatus?	sq		Comments
Phase: Article: Administration: critical descriptor lation at is the population age at is the subject health s at type of treatment popequired? at is the number of patie ected to enroll? en unmber of patients to en unmber of patients to	PO tatus?	sq		Comments
Administration: critical descriptor lation at is the population age at is the subject health s at type of treatment popequired? at is the number of patie- ceted to enroll? le number of patients to	tatus?			Comments  Ulife threatening chronic
at is the population age at is the subject health s at type of treatment pop equired? at is the number of patie ected to enroll? he number of patients to	tatus? oulation	Yes	No	☐ life threatening ☐ chronic
at is the population age at is the subject health s at type of treatment pop equired? at is the number of patie ected to enroll? he number of patients to	tatus? oulation			
at type of treatment pop equired? at is the number of patio ected to enroll? he number of patients to	oulation			
equired? at is the number of pation ected to enroll? he number of patients to			-	neartify
at is the number of patie ected to enroll? ne number of patients to	nts	10000000		
ected to enroll? ne number of patients to				
we have access to the p				
population?  7. Are the inclusion/exclusion too				
	Concerns			
8. Is this study for Clinical Reasons or				
patients need to be reci	uited			
l enrollment compete w	ith			
you expect significant a	dverse			
		Yes	No	Comments
	multiple arms?			
	g problems with	the		
?				
	ompliance issues	?		
	ed?			
departments/services?	Lab, Radiology,			
y, Pathology, CCTS: CRI	J, CRSP,			
	th inclusion/exclusion? is study for Clinical Reas demic? patients need to be recr noutside sources? Il enrollment compete w er studies? you expect significant and (AES/SAEs)? If protocol complex with protocol ethical? us foresee the IRB having us foresee any patient co- coordination with other cents/services be require departments/services?	is study for Clinical Reasons or Jemic?  Jemic?  patients need to be recruited outside sources?  Il enrollment compete with er studies?  you expect significant adverse outsides (AEs/SAEs)?  Il protocol complex with multiple arms? protocol ethical?  protosee the IRB having problems with 12 outpressee any patient compliance issues	th inclusion/exclusion? lis study for Clinical Reasons or demic? patients need to be recruited noutside sources?  Il enrollment compete with er studies? you expect significant adverse ats (AEs/SAEs)?  If protocol complex with multiple arms? protocol ethical? us foresee the IRB having problems with the light or source and patient compliance issues? coordination with other lents/services be required? departments/services? Lab, Radiology,	th inclusion/exclusion?  Is study for Clinical Reasons or demic?  patients need to be recruited noutside sources?  Ill enrollment compete with er studies? you expect significant adverse ats (AEs/SAEs)?  Protocol complex with multiple arms? protocol ethical? us foresee the IRB having problems with the 12 u foresee any patient compliance issues? oordination with other lents/services be required? departments/services? Lab, Radiology,

	7. Clinical Billables?				
	8. Duration of study?				
	9. Inpatient, outpatient or both?	MARKET AND ADDRESS OF THE PARTY AND ADDRESS OF	1001010000		
	10. Do the visits seem complex and time	25000000	1000000000		
	consuming?				
	11. Is the dosing schedule complex?				
Procedures	Procedures	Yes	No	Com	men
riocedules <b>E</b>	Are the procedures/clinical assessments				
	complex? Is there a washout period?				
	2. What procedures will be performed?	1000000	100000		
	3. Does the study collect PK samples?				
· · · · · · · · · · · · · · · · · · ·	4. Does the study require time intensive PK				
	sampling?				
	5. Is special equipment required for the study?				
Staff	Staff	Yes	No	Com	mer
Jian	Is the workload manageable?				
	2. Is additional training necessary?				
	3. What training? Start up, diaries, electronic				
	devices? Investigator meeting?	100000			
	4. Adequate staff to conduct the study?				
	5. Will the study require extended work hours, on				
	call time, weekends?	-			
	6. Additional specialists/consults needed?				
Time a Fatime at a s	7. Will budget cover expenses?	_			
Time Estimates	Time Estimates (How many hours of your time do				
	you estimate for the items below?)	_			
	1. Recruitment?	-			
,	Conducting visits (all visits)?	-			
	3. Monitor visits?	-			
	4. Addressing queries?	-			
	5. Entering data? Source docs? EDC?				
	6. Scheduling visits & procedures? Will it be				
	convenient or will pts miss work and school?				
	7. Managing adverse events?				
	8. Comments about time requirements?				
	Experience with Sponsor/CRO?				
commendations	Recommendation	1 1		Comm	nent
	Pursue protocol				
	Pursue with conditions (explain below)				
,	Do not pursue (explain below)				
	Comments:				
	Completed by:			Date:	
	Do not pursue (explain below)  Comments:			Date:	

Add Department signoffs or reviewers Use Comment areas to make notes or ask questions to sponsor.

Page 2





# Other Examples of Feasibility Tools



### UAB Abbreviated Protocol Feasibility Assessment Form

ader	Protocol Title:
	Protocol Phase: □ Phase I □ Phase II □ Phase III □ Phase IV □ Device
	□Other
	Drug Administration:   N/A  PO  SQ  IM  IV  Other Critical  Descriptor:

#### POPULATION:

- 1. What is the population age?...
- 2. What is the participant health status?  $\Box$  <u>life</u> threatening  $\Box$ chronic  $\Box$  healthy
- 3. What type of treatment population is required?
- 4. What is the number of participants expected to enroll?
- 5. Is the number of participants to be enrolled at this site realistic? □Yes □ No





Also remember to use a Recruitment and Retention Plan. A great team will have a well thought out plan of action **BEFORE** they start a study on how they are going to recruit participants and include this time and effort in their clinical trial budget.





### UAB Recruitment/Retention Plan Worksheet

1. Based upon review/search of available databases, document the number of participants who fit protocol criteria and would be contacted for participation in trial:  On what sources are you basing this number?  Medical Record Chart Review (i2b2, ICD-10 code search)  Community Database Research Database Other:  1. Please list the potential challenges you see to enrolling participants and what you would implement to overcome these issues:  Inclusion /Exclusion criteria too strict Distance/ Participant lives too far away/Participant Travel or Transportation Issues/Participant does not want to drive to UAB due to traffic/Parking Protocol requires too much from participant: procedures/frequency of visits/ duration of protocol (lasts for years) Study/Protocol will not pay participant for time to participate Age of participant population Investigational Product (IP) administration route/ requirements (multiple doses, injections, refrigeration) Randomization deterrent	<i>'</i>	Proto PI: Proto Spons As parinform	col Title: col Number: col Synopsis: cor/CRO: co
would implement to overcome these issues:  Inclusion /Exclusion criteria too strict  Distance/ Participant lives too far away/Participant Travel or Transportation Issues/Participant does not want to drive to UAB due to traffic/Parking  Protocol requires too much from participant: procedures/frequency of visits/ duration of protocol (lasts for years)  Study/Protocol will not pay participant for time to participate  Age of participant population  Investigational Product (IP) administration route/ requirements (multiple doses, injections, refrigeration)  Randomization deterrent		who fi	it protocol criteria and would be contacted for participation in trial:  nat sources are you basing this number?  Medical Record Chart Review (i2b2, ICD-10 code search)  Community Database Research Database
		would	Inclusion /Exclusion criteria too strict  Distance/ Participant lives too far away/Participant Travel or Transportation Issues/Participant does not want to drive to UAB due to traffic/Parking  Protocol requires too much from participant: procedures/frequency of visits/ duration of protocol (lasts for years)  Study/Protocol will not pay participant for time to participate  Age of participant population  Investigational Product (IP) administration route/ requirements (multiple doses, injections, refrigeration)













### Validating Enrollment Potential/ Patient Population:

- Do you have the potential subject population? Expected number to enroll? Be conservative!
- Is the inclusion/exclusion criteria realistic?
- Does the study require too much of the subject?
  - **❖** Time?
  - ❖ Cost?
- Are there extenuating circumstances that would adversely affect recruitment?
- What is the expected screen failure ratio?
- Will sponsor pay for unlimited screen fails?
- Do you have competing protocols in your department?
- Are vulnerable populations involved?





### **Protocol Considerations**:

- Do you have previous experience with the sponsor or Contract Research Organization (CRO)?
- Do you have experience in the therapeutic area under investigation?
- Are procedures consistent with standard of care? Are they realistic?
- Is the study safe, ethical and scientifically sound?
- Is the study drug dosing complex?
- Is the protocol complex, multiple arms? Duration of Study?
- Are the follow-up visits reasonable? Any clinical billables? Multiple departments?
  - Are the visit windows acceptable/and or flexible enough? Any compliance issues?
  - Do visits need to be conducted on certain days to ensure best use of protocol windows?





### **Budget Considerations/Procedure Costs:**

- Sponsor draft budget adequate? Is payment schedule reasonable?
- Will the sponsor pay for recruitment expenses?
- Does the budget include costs for administrative start-up? University required Fees?
  - ❖ IRB: drafting consent form, preparing IRB submission, Regulatory Paperwork
  - Contract: preparation and execution
  - Feasibility/Scientific Review
- Will the sponsor pay the required overhead?
- Will the sponsor pay for untimed items/events/labs/PKs as they occur? Procedures? Special equipment/training needed?
- Will the sponsor pay for document archiving, study closure, invoiceables?





### **Staff Requirements:**

- Dissect protocol using the schedule of events schematic.
  - Evaluate all tasks involved. Are after/extended hours required?
  - Feasible with current staff workload? Will budget cover effort?
- Do you have qualified and dedicated staff to coordinate the trial?
- Will staff need to be trained?
- Request and review Case Report Forms (CRFs), questionnaires to assess time commitment, lab manual to process specimens, anticipate SAEs.
- Does the PI have adequate time and scheduling availability to devote to overall supervision of the trial?
- How often will the monitor visit?
- Do you need ancillary or specialty staff (pharmacy, labs, diagnostics, etc.)?





### Facilities & Supplies:

- Is adequate clinical and office space available? Do you have storage space for supplies?
- Is special equipment required?
- Is access to emergency rescue equipment required?
- What will the sponsor supply?
  - Case Report Forms (CRFs)
  - Source documents
  - Electronic consent template
  - Packaged lab kits
  - Pre-paid shipping
  - Binders





### **COVID-19 Considerations:**

- Telemedicine Visits
- Remote follow up visits for patients
- Extra time for staff to arrange remote follow up visits and verbal consents
- Labs and procedural tests off site
- Budget/Protocol/Consent Amendments
- Management of results
- Investigational Product (IP) shipping
- Remote Monitoring





## In Summary:



#### **Subjects**

- Is population available?
- Compliance issues?
- Vulnerable population?
- Requires too much time and Money?



#### **Personnel**

- Do you have staff?
- Do you have qualified staff?
- Is sponsor specific training required?
- Are staff needed after hours/ weekends?



#### **Budget**

- Per patient cost adequate?
- \$\$ for unplanned items?
- Will sponsor pay for archiving?
- Is payment schedule reasonable?



#### **Facilities/Supplies**

- Where will procedures be performed??
- Who will perform the procedures?
- Do you have the equipment and space?
- What supplies is sponsor providing?





### Conclusion:

PLEASE consider ALL the components of a Feasibility
Assessment (FA) before starting a trial and remember
Recruitment /Retention of the participants is vital to the success
of your clinical trial and budget. At the end of a clinical trial is
important to analyze what went right/ wrong and did you cover

your costs.







### For Questions:

Please feel free to reach out to us!

CRSPtraining@uabmc.edu mfitzgerald@uabmc.edu afhenson@uabmc.edu



# Questions?

